外周T细胞淋巴瘤非特指型(PTCL-NOS):国际T细胞项目网络开发的新预后模型
国际T细胞项目网络基于前瞻性T细胞项目数据,在311例外周T细胞淋巴瘤非特指型患者中分析12项协变量,提出基于血清白蛋白、体能状态、分期和中性粒细胞绝对计数的T细胞评分模型,将患者分为低危、中危和高危三组,3年总生存率分别为76%、43%和11%(P<0.001),该评分判别能力优于既往模型。
要点
- T细胞评分基于血清白蛋白、体能状态、分期和中性粒细胞绝对计数4项协变量。
- 低危(评分0,48例,15%)、中危(评分1-2,189例,61%)、高危(评分3-4,74例,24%)。
- 三组3年总生存率分别为76%[95%CI 61-88]、43%[35-51]、11%[4-21](P<0.001)。
核心结论
- 基于临床变量的新T细胞评分可识别预后极差的外周T细胞淋巴瘤非特指型患者组。
- 与既往各模型比较,新评分对总生存的判别能力最佳。
研究设计与样本
- 研究基于前瞻性T细胞项目数据设计新模型,分析该项目收集的12项协变量。
- 纳入T细胞项目中登记的311例外周T细胞淋巴瘤非特指型患者。
- 采用多变量Cox比例风险回归分析筛选协变量。
主要发现
- 中位随访46个月时,中位总生存期和无进展生存期分别为20个月和10个月。
- 低危组48例(15%,评分0)、中危组189例(61%,评分1-2)、高危组74例(24%,评分3-4)。
- 低危、中危、高危组3年总生存率分别为76%[95%CI 61-88]、43%[35-51]、11%[4-21](P<0.001)。
关键数值与推荐
- T细胞评分基于血清白蛋白、体能状态、分期和中性粒细胞绝对计数4项协变量。
- 评分0为低危,评分1-2为中危,评分3-4为高危。
- 新评分对总生存的判别能力优于既往各模型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Different models to investigate the prognosis of peripheral T cell lymphoma not otherwise specified (PTCL-NOS) have been developed by means of retrospective analyses. Here we report on a new model designed on data from the prospective T Cell Project. Twelve covariates collected by the T Cell Project were analysed and a new model (T cell score), based on four covariates (serum albumin, performance status, stage and absolute neutrophil count) that maintained their prognostic value in multiple Cox proportional hazards regression analysis was proposed. Among patients registered in the T Cell Project, 311 PTCL-NOS were retained for study. At a median follow-up of 46 months, the median overall survival (OS) and progression-free survival (PFS) was 20 and 10 months, respectively. Three groups were identified at low risk (LR, 48 patients, 15%, score 0), intermediate risk (IR, 189 patients, 61%, score 1-2), and high risk (HiR, 74 patients, 24%, score 3-4), having a 3-year OS of 76% [95% confidence interval 61-88], 43% [35-51], and 11% [4-21], respectively (P < 0·001). Comparing the performance of the T cell score on OS to that of each of the previously developed models, it emerged that the new score had the best discriminant power. The new T cell score, based on clinical variables, identifies a group with very unfavourable outcomes.
引用
- Federico M, Bellei M, Marcheselli L, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018. PMID: 29672827. doi:10.1111/bjh.15258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。